Wealthquest Corp Acquires New Stake in Pfizer Inc. (PFE)

Wealthquest Corp purchased a new stake in Pfizer Inc. (NYSE:PFE) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 19,875 shares of the biopharmaceutical company’s stock, valued at approximately $867,000.

A number of other hedge funds also recently made changes to their positions in the stock. Home Federal Bank of Tennessee boosted its stake in Pfizer by 0.8% in the fourth quarter. Home Federal Bank of Tennessee now owns 29,695 shares of the biopharmaceutical company’s stock worth $1,297,000 after purchasing an additional 249 shares in the last quarter. Advocacy Wealth Management Services LLC boosted its stake in Pfizer by 48.2% in the fourth quarter. Advocacy Wealth Management Services LLC now owns 793 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 258 shares in the last quarter. Viridian Ria LLC boosted its stake in Pfizer by 0.9% in the fourth quarter. Viridian Ria LLC now owns 30,859 shares of the biopharmaceutical company’s stock worth $1,327,000 after purchasing an additional 280 shares in the last quarter. Trust Co. of Oklahoma boosted its stake in Pfizer by 4.4% in the fourth quarter. Trust Co. of Oklahoma now owns 7,079 shares of the biopharmaceutical company’s stock worth $309,000 after purchasing an additional 300 shares in the last quarter. Finally, Capital City Trust Co. FL boosted its stake in Pfizer by 6.9% in the fourth quarter. Capital City Trust Co. FL now owns 5,139 shares of the biopharmaceutical company’s stock worth $224,000 after purchasing an additional 330 shares in the last quarter. 69.49% of the stock is currently owned by institutional investors and hedge funds.

A number of research firms have commented on PFE. JPMorgan Chase & Co. reissued a “neutral” rating and issued a $46.00 price objective on shares of Pfizer in a research note on Friday. Zacks Investment Research raised Pfizer from a “sell” rating to a “hold” rating in a research note on Wednesday, April 10th. Bank of America boosted their price objective on Pfizer from $45.00 to $48.00 and gave the stock a “buy” rating in a research note on Monday, April 1st. Citigroup reissued a “neutral” rating and issued a $41.00 price objective on shares of Pfizer in a research note on Wednesday, February 20th. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $53.00 price objective on shares of Pfizer in a research note on Tuesday, February 19th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and seven have issued a buy rating to the company. Pfizer presently has a consensus rating of “Hold” and an average target price of $45.61.

In other news, insider Alexander R. Mackenzie sold 15,000 shares of the business’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $42.83, for a total transaction of $642,450.00. Following the completion of the sale, the insider now owns 124,994 shares in the company, valued at $5,353,493.02. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Mikael Dolsten sold 149,553 shares of the business’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $43.55, for a total value of $6,513,033.15. Following the sale, the insider now owns 390,097 shares of the company’s stock, valued at approximately $16,988,724.35. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 332,526 shares of company stock valued at $14,346,539. 0.09% of the stock is currently owned by corporate insiders.

PFE stock opened at $39.38 on Friday. The firm has a market cap of $234.42 billion, a PE ratio of 13.13, a PEG ratio of 2.37 and a beta of 0.75. Pfizer Inc. has a twelve month low of $34.37 and a twelve month high of $46.47. The company has a quick ratio of 1.33, a current ratio of 1.57 and a debt-to-equity ratio of 0.52.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, January 29th. The biopharmaceutical company reported $0.64 earnings per share for the quarter, topping analysts’ consensus estimates of $0.63 by $0.01. The company had revenue of $13.98 billion during the quarter, compared to the consensus estimate of $13.92 billion. Pfizer had a return on equity of 26.02% and a net margin of 20.79%. The firm’s quarterly revenue was up 2.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.62 earnings per share. On average, equities research analysts predict that Pfizer Inc. will post 2.86 earnings per share for the current fiscal year.

WARNING: “Wealthquest Corp Acquires New Stake in Pfizer Inc. (PFE)” was originally posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this piece on another domain, it was stolen and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.baseballdailydigest.com/news/2019/04/21/wealthquest-corp-acquires-new-stake-in-pfizer-inc-pfe.html.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Story: Moving Average Convergence Divergence (MACD)

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.